Arcutis director sells 4,730 shares, exercises options

Q: What insider stock transactions were reported at Arcutis Biotherapeutics (ARQT)?

Howard G. Welgus reported a sale of 4,730 Common Stock shares at $26.91 and exercised stock options to acquire 2,255, 1,019 and 822 shares. These transactions occurred on July 15, 2026 and adjusted his direct ownership position.

Q: How many Arcutis Biotherapeutics (ARQT) shares does Howard G. Welgus hold after the transactions?

After the reported trades, Howard G. Welgus directly owned 37,109 shares of Arcutis Biotherapeutics Common Stock. This figure reflects the combined effect of the option exercises and the sale of 4,730 shares executed on July 15, 2026.

Q: At what prices did the Arcutis Biotherapeutics (ARQT) director transact his shares and options?

Welgus sold 4,730 shares at $26.91 per share and exercised stock options at $8.63, $7.51 and $6.5223 per share. These exercise prices reflect the strike prices of three separate stock option grants converted into Common Stock.

Q: Were the recent ARQT insider trades by Howard G. Welgus under a 10b5-1 plan?

Yes. All reported transactions were effected pursuant to a 10b5-1 trading plan adopted on March 13, 2026, with a plan end date of June 15, 2027. This indicates the trades followed a pre-arranged trading program.

Q: What derivative securities were involved in the Arcutis Biotherapeutics (ARQT) Form 4 filing?

The filing shows exercises of Stock Options (right to buy) covering 2,255, 1,019 and 822 underlying Common shares, at exercise prices of $8.63, $7.51 and $6.5223. Each option was reported as fully vested at the time of exercise.

Arcutis Biotherapeutics director Howard G. Welgus reported multiple Common Stock transactions on July 15, 2026.

Filing Impact

(Neutral)

Filing Sentiment

(Neutral)How Sentiment works

Sentiment and the balance of points

Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.

How Sentiment works How the balance works

Form Type

Rhea-AI Filing Summary

Arcutis Biotherapeutics director Howard G. Welgus reported multiple Common Stock transactions on July 15, 2026. He sold 4,730 shares at $26.91 per share and exercised stock options to acquire 2,255, 1,019 and 822 shares at exercise prices of $8.63, $7.51 and $6.5223, respectively. Following these trades, he directly owned 37,109 shares of Common Stock. All transactions were effected pursuant to a 10b5-1 trading plan adopted on March 13, 2026, with a plan end date of June 15, 2027.

Insider Trade Summary 10b5-1

Exercise and sale activity reported; no spread calculated

Exercise and Sale 7 txns

Insider Welgus Howard G.

Role Director

Sold 4,730 shs ($127K)

Approx. gross sale proceeds $127K

Approx. exercise cost $32K

Type	Security	Shares	Price	Value
Exercise	Stock Option (right to buy) ^{F1, F2}	822	$0.00	$0.00
Exercise	Stock Option (right to buy) ^{F1, F2}	1,019	$0.00	$0.00
Exercise	Stock Option (right to buy) ^{F1, F2}	2,255	$0.00	$0.00
Exercise	Common Stock ^F1	822	$6.5223	$5K
Exercise	Common Stock ^F1	1,019	$7.51	$8K
Exercise	Common Stock ^F1	2,255	$8.63	$19K
Sale	Common Stock ^F1	4,730	$26.91	$127K

Holdings After Transaction: Stock Option (right to buy) — 40,942 contracts (Direct); Common Stock — 37,109 shares (Direct)

Footnotes (2)

F1. The transaction reported in this Form 4 was effected pursuant to a 10b5-1 trading plan adopted on March 13, 2026, by the Reporting Person, with a plan end date of June 15, 2027.
F2. The option is fully vested.

Key Figures

Common shares sold: 4,730 shares Sale price: $26.91 per share Shares from option exercises: 2,255; 1,019; 822 shares +3 more

6 metrics

Common shares sold 4,730 shares Common Stock sale on July 15, 2026

Sale price $26.91 per share Price for 4,730-share Common Stock sale on July 15, 2026

Shares from option exercises 2,255; 1,019; 822 shares Common shares acquired via three stock option exercises on July 15, 2026

Post-transaction common holdings 37,109 shares Directly owned Common Stock following reported transactions

10b5-1 plan adoption date March 13, 2026 Adoption date of 10b5-1 trading plan governing these transactions

10b5-1 plan end date June 15, 2027 End date of 10b5-1 trading plan noted in footnote

Key Terms

10b5-1 trading plan, Stock Option (right to buy), Exercise or conversion of derivative security

3 terms

10b5-1 trading plan regulatory

"effected pursuant to a 10b5-1 trading plan adopted on March 13, 2026"

A 10b5-1 trading plan is a pre-arranged strategy that allows company insiders to buy or sell company stock at set times, regardless of their current knowledge about the company's situation. It acts like a scheduled appointment for trading, helping prevent the appearance of impropriety or insider trading. This plan provides a way for insiders to sell or buy shares in a controlled, transparent manner, offering reassurance to investors about fair trading practices.

Stock Option (right to buy) financial

"security_title: Stock Option (right to buy) with underlying Common Stock"

Exercise or conversion of derivative security financial

"transaction_code_description: Exercise or conversion of derivative security"

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider stock transactions were reported at Arcutis Biotherapeutics (ARQT)?

Howard G. Welgus reported a sale of 4,730 Common Stock shares at $26.91 and exercised stock options to acquire 2,255, 1,019 and 822 shares. These transactions occurred on July 15, 2026 and adjusted his direct ownership position.

How many Arcutis Biotherapeutics (ARQT) shares does Howard G. Welgus hold after the transactions?

After the reported trades, Howard G. Welgus directly owned 37,109 shares of Arcutis Biotherapeutics Common Stock. This figure reflects the combined effect of the option exercises and the sale of 4,730 shares executed on July 15, 2026.

At what prices did the Arcutis Biotherapeutics (ARQT) director transact his shares and options?

Welgus sold 4,730 shares at $26.91 per share and exercised stock options at $8.63, $7.51 and $6.5223 per share. These exercise prices reflect the strike prices of three separate stock option grants converted into Common Stock.

Were the recent ARQT insider trades by Howard G. Welgus under a 10b5-1 plan?

Yes. All reported transactions were effected pursuant to a 10b5-1 trading plan adopted on March 13, 2026, with a plan end date of June 15, 2027. This indicates the trades followed a pre-arranged trading program.

What derivative securities were involved in the Arcutis Biotherapeutics (ARQT) Form 4 filing?

The filing shows exercises of Stock Options (right to buy) covering 2,255, 1,019 and 822 underlying Common shares, at exercise prices of $8.63, $7.51 and $6.5223. Each option was reported as fully vested at the time of exercise.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google

Accepted by SEC EDGAR 07/17/2026 - 04:01 PM EDT

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Welgus Howard G.

(Last)

(First)

(Middle)

C/O ARCUTIS BIOTHERAPEUTICS, INC.

3027 TOWNSGATE ROAD, SUITE 300

(Street)

WESTLAKE VILLAGE

CALIFORNIA

91361

(City)

(State)

(Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Arcutis Biotherapeutics, Inc. [ ARQT ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director	10% Owner
	Officer (give title below)	Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
07/15/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	Amount	(A) or (D)	Price		6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
Common Stock	07/15/2026		M⁽¹⁾		822	A	$6.5223	38,565	D
Common Stock	07/15/2026		M⁽¹⁾		1,019	A	$7.51	39,584	D
Common Stock	07/15/2026		M⁽¹⁾		2,255	A	$8.63	41,839	D
Common Stock	07/15/2026		S⁽¹⁾		4,730	D	$26.91	37,109	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	8. Price of Derivative Security (Instr. 5)		10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
Stock Option (right to buy)	$6.5223	07/15/2026		M⁽¹⁾			822	⁽²⁾	11/20/2029	Common Stock	822	$0	8,218	D
Stock Option (right to buy)	$7.51	07/15/2026		M⁽¹⁾			1,019	⁽²⁾	05/31/2033	Common Stock	1,019	$0	10,182	D
Stock Option (right to buy)	$8.63	07/15/2026		M⁽¹⁾			2,255	⁽²⁾	06/14/2034	Common Stock	2,255	$0	22,542	D

Explanation of Responses:

1. The transaction reported in this Form 4 was effected pursuant to a 10b5-1 trading plan adopted on March 13, 2026, by the Reporting Person, with a plan end date of June 15, 2027.

2. The option is fully vested.

Remarks:

	/s/ Latha Vairavan, as Attorney-in-Fact for Howard G. Welgus	07/17/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

Source: View Original Filing on SEC EDGAR